We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

487 hedge funds and large institutions have $13.1B invested in Abiomed Inc in 2021 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 160 increasing their positions, 192 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more call options, than puts

Call options by funds: $104M | Put options by funds: $65.7M

2% less funds holding

Funds holding: 498487 (-11)

5% less capital invested

Capital invested by funds: $13.9B → $13.1B (-$726M)

12% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 59

17% less repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 192

50% less funds holding in top 10

Funds holding in top 10: 84 (-4)

Holders
487
Holders Change
-11
Holders Change %
-2.21%
% of All Funds
8.55%
Holding in Top 10
4
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-50%
% of All Funds
0.07%
New
52
Increased
160
Reduced
192
Closed
59
Calls
$104M
Puts
$65.7M
Net Calls
+$38.6M
Net Calls Change
+$39.8M

ABMD Hedge Fund Activity: Q1 2021 in Review

487 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q1 2021, worth a combined $13.1B — down 5.2% from $13.9B a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of ABMD and 52 opened new positions — a net loss of 7 holders — while 192 trimmed existing stakes and 160 added.

The largest buyer was Baillie Gifford & Co, adding an estimated $128M. The largest seller was Sands Capital Management, exiting entirely with an estimated $480M sold.

  • 487 institutional investors held Abiomed Inc (ABMD) as of Q1 2021, down from 498 in Q4 2020.
  • Funds reported $13.1B of Abiomed Inc stock for Q1 2021, down 5.2% quarter-over-quarter.
  • 52 funds opened new Abiomed Inc positions in Q1 2021 and 59 closed out, a net change of -7 holders.
  • The largest Abiomed Inc buyer in Q1 2021 was Baillie Gifford & Co, an estimated $128M added.
  • The largest Abiomed Inc seller in Q1 2021 was Sands Capital Management, an estimated $480M sold.

Based on aggregated 13F filings for Q1 2021.